Evidence map›Paper›PMID 38812760›Full record

ArticleActa medica Philippina2024

Applying Network Pharmacology and Molecular Docking in the Screening for Molecular Mechanisms of Ampalaya (

Robertson G Rivera, Patrick Junard S Regidor, Edwin C Ruamero, Czarina Dominique R Delos Santos, Clinton B Gomez, Eric John V Allanigue, Melanie V Salinas

Abstract read
In one paragraph

Article in Acta medica Philippina, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Jiangtang Decoction for Type 2 Diabetes and NAFLD: Integrative AnalysisEndocrine, metabolic & immune disorders drug targets · 2026
    Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Robertson G RiveraDepartment of Pharmaceutical Chemistry, College of Pharmacy, University of the Philippines Manila, Manila, Philippines.
Patrick Junard S RegidorDepartment of Pharmaceutical Chemistry, College of Pharmacy, University of the Philippines Manila, Manila, Philippines.
Edwin C RuameroDepartment of Pharmaceutical Chemistry, College of Pharmacy, University of the Philippines Manila, Manila, Philippines.
Czarina Dominique R Delos SantosDepartment of Pharmaceutical Chemistry, College of Pharmacy, University of the Philippines Manila, Manila, Philippines.
Clinton B GomezDepartment of Industrial Pharmacy, College of Pharmacy, University of the Philippines Manila, Manila, Philippines.
Eric John V AllanigueDepartment of Pharmacology and Toxicology, College of Medicine, University of the Philippines Manila, Manila, Philippines.
Melanie V SalinasMedical Device Clinical Research, Safety and Medical Affairs Department, Clinchoice, Inc., Fort Washington, Pennsylvania, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background and Objectives: Type 2 diabetes mellitus (T2DM) is a global health concern affecting more than 400 million people worldwide. Diabetic neuropathy, nephropathy, retinopathy, and cardiovascular complications lead to debilitating effects to patients. To prevent these, the treatment goal is to lower the blood sugar levels and maintain at a normal range which is achieved through conventional treatments like insulin and oral hypoglycemic agents. However, the high cost of these medications implicates patient treatment outcomes. Hence, alternatives are sought for including the use of herbal medicines. Methods: Network pharmacology was employed to determine pivotal proteins that are targeted by MC and LS compounds. Molecular docking was then done to evaluate the favorability of the binding of these compounds toward their target proteins. Results: Our results showed that TNF, HSP90AA1, MAPK3, ALDH2, GCK, AKR1B1, TTR and RBP4 are the possible pivotal targets of MC and LS compounds in T2DM. Conclusion: Terpenoids from MC and decanoic acid from LS are the compounds which showed favorable binding towards pivotal protein targets in T2DM. By binding towards the different key proteins in T2DM, they may exhibit their synergistic effects. However, the results of this study are bound to the limitations of computational methods and experimental validation are needed to verify our findings.

Indexed as

Lagerstroemia speciosamolecular dockingMomordica charantianetwork pharmacologyT2DM

Identifiers

PMID38812760
PMCPMC11132292

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.